Recurrent Melanoma Completed Phase 3 Trials for Aldesleukin (DB00041)

Also known as: Melanoma Recurrent

IndicationStatusPhase
DBCOND0028662 (Recurrent Melanoma)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00019682Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic MelanomaTreatment